Published in PLoS One on February 24, 2014
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci (2015) 0.95
Epigenetics across the human lifespan. Front Cell Dev Biol (2014) 0.93
WNT-5A: signaling and functions in health and disease. Cell Mol Life Sci (2015) 0.86
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene (2015) 0.79
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia (2016) 0.77
PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep (2016) 0.77
Pias1 is essential for erythroid and vascular development in the mouse embryo. Dev Biol (2016) 0.76
SUMO and the robustness of cancer. Nat Rev Cancer (2017) 0.75
Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem Cell Reports (2016) 0.75
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The epigenomics of cancer. Cell (2007) 30.91
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Cancer stem cells: models and concepts. Annu Rev Med (2007) 8.06
Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol (2006) 7.36
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature (2008) 4.60
Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A (1998) 4.12
Cancer stem cells in solid tumors. Curr Opin Biotechnol (2007) 3.91
Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol (2008) 3.87
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol (2004) 3.34
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol (2005) 2.59
PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol (2004) 2.52
Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell (2003) 2.49
Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res (2001) 1.95
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell (2007) 1.89
Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth. Development (2007) 1.85
WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res (2008) 1.67
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
The epigenetics of breast cancer. Mol Oncol (2010) 1.57
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Negative regulation of NF-kappaB signaling by PIAS1. Mol Cell Biol (2005) 1.38
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res (2000) 1.32
Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci (2001) 1.29
Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc Natl Acad Sci U S A (2007) 1.28
The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science (2010) 1.27
Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability. Proc Natl Acad Sci U S A (2013) 1.24
Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol Sci (2008) 1.10
Regulation of the sumoylation system in gene expression. Curr Opin Cell Biol (2008) 1.09
Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.05
WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood (2007) 1.04
c-myc protein in normal tissue. Effects of fixation on its apparent subcellular distribution. Am J Pathol (1988) 1.03
LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS Lett (2005) 0.99
Unravelling the epigenomic dimension of breast cancers. Curr Opin Oncol (2011) 0.94
Glycodelin in ovarian serous carcinoma: association with differentiation and survival. Cancer Res (2003) 0.93
Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. Cancer Sci (2007) 0.91
Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer (2003) 0.91
Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ (1997) 0.84
Glycodelin reduces breast cancer xenograft growth in vivo. Int J Cancer (2008) 0.83
Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett (2005) 0.83